Lupin's LNP8701 Phase 1 Data Accepted for ASCO 2026 Meeting
Lupin's Phase 1a trial data for LNP8701, a novel SOS1 inhibitor, accepted for ASCO 2026 Annual Meeting (May 29-June 2). LNP8701 showed favorable safety, tolerability, and anti-tumor activity. Two patients completed 12 cycles, one completed 14 cycles with stable disease. Phase 1b trial ongoing.
The announcement pertains to early-stage clinical trial data (Phase 1) for a novel drug candidate. While positive, the full impact on Lupin's business will depend on further trial phases and eventual market approval.
The announcement highlights positive results from a Phase 1 trial, indicating favorable safety, tolerability, and anti-tumor activity of LNP8701, which is encouraging for future cancer therapies.
Lupin Limited announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The meeting is scheduled to take place from May 29 to June 2, 2026, in Chicago, IL.
The abstract, titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors," has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and is available on the ASCO website.
The findings are from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an investigational, orally administered SOS1 (Son of Sevenless1) inhibitor designed to block SOS1-mediated RAS activation, limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with a desirable safety and pharmacokinetic profile, along with favorable anti-tumor activity. Preliminary efficacy data showed that two patients completed LNP8701 monotherapy for 12 cycles (one year), and one patient completed 14 cycles with stable disease.
Vinita Gupta, CEO of Lupin, stated, “The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes.”
Current data suggest LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors as both a monotherapy and in combination therapy.
Details of the abstract include Abstract Number: e15162, Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology, Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162), DOI: 10.1200/JCO.2026.44.16_suppl.e15162, Clinical Trial Registration Number: CTRI/2024/08/072373, and an abstract link.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.